Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study
Cancer Letters · 2024-08 · 598 · 217100
DOI: 10.1016/j.canlet.2024.217100 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Kevin Sheng-Kai Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Global Health, Perelman School of M…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Periodontitis, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Merck.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs) across various organ systems including oral health complications such as dry mouth and stomatitis. In this study, we aimed to determine the risk of periodontitis among patients on immune checkpoint inhibitors (ICIs) and to test the associations between ICI-associated periodontitis and other immune-related adverse events (irAEs). We performed a retrospective cohort study involving adult cancer patients between January 2010 and November 2021. Patients on an ICI were propensity score-matched to patients not on an ICI. The primary outcome was the occurrence of periodontitis. ICIs included programmed cell death 1 (PD-1) inhibitors programmed cell death ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors. The risk of periodontitis following ICI use was derived through a Cox proportional hazard model and Kaplan-Meier survival analysis. Overall, 868 patients on an ICI were matched to patients not on an ICI. Among the ICI cohort, 41 (4.7 %) patients developed periodontitis. The incidence rate of periodontitis was significantly higher in patients on an ICI than in patients not on an ICI (55.3 vs 25.8 per 100 patient-years, incidence rate ratio = 2.14, 95 % CI = 1.38-3.33). Both the use of PD-L1 inhibitors (multivariate HR = 2.5, 95%CI = 1.3-4.7) and PD-1 inhibitors (multivariate HR = 2.0, 95%CI = 1.2-3.2) were associated with the risk of periodontitis. The presence of immune-related periodontitis was associated with better overall survival (not reached vs 17 months, log-rank p-value
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
- Harvard School of Dental Medicine, Boston, MA, USA.
- Department of Environmental and Occupational Medicine, National Taiwan University Hospital, Taipei, Taiwan; London School of Hygiene & Tropical Medicine, London, UK.
- Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine, Boston, MA, USA; Center for Clinical and Translational Research, ADA Forsyth Institute, Cambridge, MA, USA.
Förderung
- Merck
Zitieren
APA
Ma, K. S., Chiang, C. H., Chen, S. T., Dinh, Y., Chiang, C. H., Van Dyke, T. E., Sullivan, R., Ananthakrishnan, A. N., Hsia, Y. P., Peng, C. M., & Chiang, C. H. (2024). Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study. Cancer Letters, 598, 217100. https://doi.org/10.1016/j.canlet.2024.217100
Vancouver
Ma KS, Chiang CH, Chen ST, Dinh Y, Chiang CH, Van Dyke TE, et al. Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study. Cancer Letters. 2024;598:217100. doi:10.1016/j.canlet.2024.217100
BibTeX
@article{Ma2024,
author = {Ma, Kevin Sheng-Kai and Chiang, Cho-Hung and Chen, Steven T and Dinh, Yen and Chiang, Cho-Hsien and Van Dyke, Thomas E and Sullivan, Ryan and Ananthakrishnan, Ashwin N and Hsia, Yuan Ping and Peng, Cheng-Ming and Chiang, Cho-Han},
title = {Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study},
journal = {Cancer Letters},
year = {2024},
volume = {598},
pages = {217100},
doi = {10.1016/j.canlet.2024.217100}
}
EUVIMED